Hsbc Holdings PLC Increases Stock Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Hsbc Holdings PLC grew its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 33.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 90,061 shares of the biotechnology company's stock after purchasing an additional 22,814 shares during the period. Hsbc Holdings PLC's holdings in BioCryst Pharmaceuticals were worth $677,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Venturi Wealth Management LLC purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at approximately $46,000. R Squared Ltd purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at approximately $48,000. KBC Group NV lifted its position in shares of BioCryst Pharmaceuticals by 80.1% during the 4th quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after buying an additional 4,537 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter valued at approximately $80,000. Finally, Mariner LLC lifted its position in shares of BioCryst Pharmaceuticals by 32.1% during the 4th quarter. Mariner LLC now owns 13,258 shares of the biotechnology company's stock valued at $100,000 after buying an additional 3,224 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Stock Up 0.6%

Shares of BCRX traded up $0.06 during midday trading on Friday, reaching $9.98. The company had a trading volume of 7,606,302 shares, compared to its average volume of 2,989,382. BioCryst Pharmaceuticals, Inc. has a 1-year low of $5.34 and a 1-year high of $11.11. The stock has a market cap of $2.09 billion, a PE ratio of -16.36 and a beta of 1.08. The firm has a 50 day simple moving average of $7.87 and a 200-day simple moving average of $7.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same period in the previous year, the business earned $0.28 earnings per share. The firm's revenue was up 40.8% on a year-over-year basis. As a group, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BCRX. Evercore ISI increased their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a research report on Monday, January 13th. Cantor Fitzgerald initiated coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an "overweight" rating and a $20.00 target price on the stock. JPMorgan Chase & Co. raised their price objective on BioCryst Pharmaceuticals from $10.00 to $13.00 and gave the company an "overweight" rating in a report on Tuesday, May 6th. Needham & Company LLC raised their price objective on BioCryst Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Finally, StockNews.com upgraded BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Tuesday, May 6th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals has an average rating of "Buy" and a consensus target price of $16.56.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.